All attending UK organisations

UK companies attending Bio-Europe Spring as part of the official delegation
(Click here to search profiles)
Almac Discovery, Almac Group, Barrington James, BioIndustry Association (BIA), BioPartner UK, Bit Bio, Camena Bioscience, Catalyst Clinical Research, Frontier Sciences (Scotland), Fusion Antibodies, InSilicoTrials Technologies, Isogenica, LSX, Medherant, MediSieve, MediWales, Mursla, National Institute for Health and Care Research (NIHR), Nevrargenics, Oncimmune, PrecisionLife, Research Donors, Rosemont Pharmaceuticals, S. M. Discovery Group (SMDG), Scendea, Scottish Development International, Sekisui, Silence Therapeutics, SomaServe, Sygnature Discovery, Viramal (31).

UK Exhibitors
BioPartner UK: UK stand, booth #90 with Catalyst Clinical Research, InSilicoTrials Technologies, and National Institute for Health and Care Research (NIHR)
Barrington James: booth 100
One Nucleus with their delegation of members: booth 46, OBN with their delegation of members: booth 11, Cancer Research Horizons booth 34, Porton booth 8, Symbiosis booth 17.

Other UK companies associated with the delegation*:
C4X Discovery, Cancer Research Horizons, Catalyst Advisors, CatSci, Curileum Discovery, Department for Business and Trade, Etcembly, Exscientia, Intelligent OMICS, Mereo BioPharma, Norgine, PharmaVentures, Present Value, ProImmune, Sachs Associates, Sixfold Bio, TRAFIK Productions, VirdisGroup (18).

All attending UK companies:
4basebio Discovery, 4 MCS, Abacus Medicine Pharma Services, Accession Therapeutics, Acclime, Achilles Therapeutics, Actigen, Adrestia Therapeutics, Advanz Pharma, Alacrita Consulting, Alchemab Therapeutics, Almac Discovery, Almac Group, AlphaSense, Alvotech, Antev, Antiverse, APM Health Europe, Aptamer Group, Aptorum Group , Asieris Pharmaceutical, Aspire Pharma, Astorg, Autolus, Avacta Therapeutics, Barrington James, Basecamp Research, BenevolentAI, BerGenBio, Biogen Idec, BioIndustry Association (BIA), BioPartner UK, Biopharma Process Systems, Bit Bio, BiVictriX Therapeutics, Bloomsbury Genetic Therapies, Bristol Myers Squibb, Business Sweden, C4X Discovery, Camena Bioscience, Cancer Research Horizons, Catalyst Advisors, Catalyst Clinical Research, CatSci, CBPE CAPITAL, CEPI, Ciloa, Clarivate, ClearView Healthcare Partners, Cerevance, CG Results, Charles River Labs, Charm Therapeutics, Chiesi, Chromatin Bioscience, Citeline, Clinigen, CMS Cameron McKenna Nabarro Olswang, CNX Therapeutics, Constructive Bio,Cumulus Oncology, Curileum Discovery, Curve Therapeutics, DealCloud by Intapp, Decisive Consulting, Dementia Discovery Fund, Department for International Trade, DLRC, Domainex, Edinburgh Innovations, Edinburgh Molecular Imaging, Eisai, Elanco Animal Health, Element, Ellipses Pharma, Endpoint Clinical, Epitopea, Eptiva Therapeutics, Ergomed, Essential Pharma, Etcembly, e -therapeutics, Evaluate, Eversana, Evotec, Exonate, Exosla Therapeutics, Exscientia, FHI Clinical, F-Prime Capital, Frontier Science (Scotland), Fusion Antibodies, George Medicines, GJE, GlobalData Healthcare, Global Mutual, GSK, HealthCare Royalty, Healx, HungaroTrial CRO, hVIVO, Idea Regulatory, IK Partners, Iksuda Therapeutics, ImmuPharma, Innovent Biologics (Europe), IN-PART, InsilicoTrials Technologies, Intelligent OMICS, Investment NSW, Ipsen, IQVIA, Isogenica, Isomerase Therapeutics, Johnson & Johnson Innovation, Kent Pharma UK, KBio, Koi Consulting Partners, Kuano, Kx Advisors, Kynos Therapeutics, Kyowa Kirin, Labcorp Drug Development, Lifebit, LifeScience, LiliumX, Lilly, Liminal BioSciences, Lonza, Lou Investments, LSX, Medherant, MediSieve, MediWales, MedPharm , Mereo BioPharma, Midatech Pharma, Mironid, Mitsubishi Tanabe Pharma, Monument Tx, MSD, Mundipharma International, Mursla Bio, Nanomerics, National Institute for Health and Care Research (NIHR), Nature Biotech, Neophore, Nevrargenics, Nordic Pharma, Norgine, Novotech, Oak Zone Biotech UK, OBN (UK), Ochre Bio, Oncimmune, OncoBone Ventures, One Nucleus, Ono Pharmaceutical, Ora Clinical, Orbit Discovery, Orchard Therapeutics, Otsuka Pharmaceutical Europe, Oval Medical Technologies, Oxford Biomedica, Oxford Biotherapeutics, Phaim Pharma, Pharma and Safety Solutions, PharmaCircle, pharmaphorum Media, Pharmaron UK, PharmaVentures Pricing & Market Access, PHAsT (University of Sheffield), PhoreMost, Physiomics, Pioneer Group, Pracipio, PrecisionLife, Premier Research, Present Value, Proclinical, ProImmune, ProPharma, Putnam Associates, Quotient Sciences, Rallybio, RBW Consulting, Receptor.ai, Reneuron Group plc, Research Donors, RHA Communications, Roquefort Therapeutics, Rosemont Pharmaceuticals, S. M. Discovery Group (SMDG), Sage Healthcare, Sano Genetics, Sapio Sciences, Scendea, Scius Communications, Scottish Development International Scottish Enterprise, Sekisui, Serac Healthcare, SGS Quay Pharmaceuticals, Shionogi, Silence Therapeutics, Simbec -Orion, Simcere Pharmaceutical Group, Sitryx Therapeutics, Sixfold, SJ Sourcing, SLA Pharma, Somaserve, Springer Nature, SpyBiotech, Stablepharma, Standigm, State Government of Victoria, Storm Therapeutics, Strike Pharma AB, Sygnature Discovery, Symbiosis Pharmaceutical Services, Syneos Health, SynOx Therapeutics, Tanner Pharma, Teijin Pharma, The Fulford Group, Theolytics, Theradex Oncology, Theramex, Tiziana, Torreya, tranScrip, True Search, Ubiquigent, Ulster University, University of Cambridge Enterprise, University of Reading, University of Southampton, Upperton Pharma Solutions, Valirx, Vectura, Vernalis R&D, Viatria Inc, Viramal, William Reed Business Media, WuXi AppTec, WuXi Biologics. (242)